Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07206745Not ApplicableNot Yet Recruiting

A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infections

Role: collaborator

NCT06918353Not Yet Recruiting

The Severity Assessment Model for AECOPD With Combination of Disease and Syndrome

Role: collaborator

NCT06747325Not ApplicableNot Yet Recruiting

Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia

Role: collaborator

NCT06673121Recruiting

Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule

Role: lead

NCT06373692Not Yet Recruiting

REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma)

Role: collaborator

NCT05841901Not ApplicableUnknown

Huang-long Zhi-xiao Granule Improves the Control Rate of Chronic Persistent of Asthma

Role: collaborator

NCT00548223Phase 4Completed

The Secondary Prevention Trial for Ischemic Stroke With DengzhanShengmai Capsule

Role: collaborator

All 7 trials loaded